| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:Prasinezumab (anti-Alpha-synuclein)
CAS:1960462-19-4
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K14103
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Prasinezumab
CAS:1960462-19-4
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Prasinezumab
CAS:1960462-19-4
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Prasinezumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Prasinezumab(DHE22002)
CAS:1960462-19-4
Purity:PAGE:>95% Package:100ug;1mg
|
|
| | Prasinezumab Basic information |
| Product Name: | Prasinezumab | | Synonyms: | Prasinezumab;Research Grade Prasinezumab;Prasinezumab (anti-Alpha-synuclein);Research Grade Prasinezumab(DHE22002) | | CAS: | 1960462-19-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Prasinezumab Structure]() |
| | Prasinezumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Prasinezumab Usage And Synthesis |
| Uses | Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research[1]. | | IC 50 | α-synuclein Aggregation | | References | [1] Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407. DOI:10.3389/fneur.2021.705407 |
| | Prasinezumab Preparation Products And Raw materials |
|